Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGT2B7 | P16662 | 8/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.32 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL956392 | 1.00 | UGT2B7 (0.51) | UGT2B7CYP1A2PTPN2PTPN1TSHR | |
| SCHEMBL20245300 | 0.83 | PTPN2 (0.48) | UGT2B7PTPN2PTPN1 | |
| SCHEMBL956449 | 0.76 | UGT2B7 (0.34) | UGT2B7PTPN2PTPN1 | |
| SCHEMBL956451 | 0.76 | UGT2B7 (0.34) | UGT2B7PTPN2PTPN1 | |
| SCHEMBL18472141 | 0.74 | EPHX2 (0.41) | — | |
| SCHEMBL960104 | 0.73 | UGT2B7 (0.38) | UGT2B7TP53 | |
| SCHEMBL960105 | 0.73 | UGT2B7 (0.38) | UGT2B7TP53 | |
| SCHEMBL30706319 | 0.73 | PTPN2 (0.43) | UGT2B7PTPN2PTPN1 | |
| SCHEMBL18472139 | 0.72 | EPHX2 (0.38) | CYP1A2PTPN2PTPN1 | |
| SCHEMBL954543 | 0.72 | UGT2B7 (0.52) | UGT2B7CYP1A2PTPN2PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3100723-B1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | BIKAM PHARMACEUTICALS INC (US) | 2019-06-12 | — | — | EP | disclosed |
| US-20170037018-A1 | Opsin-Binding Ligands, Compositions and Methods of Use | BIKAM PHARMACEUTICALS INC. (US) | 2017-02-09 | — | — | US | disclosed |
| US-9562022-B2 | Opsin-binding ligands, compositions and methods of use | BIKAM PHARMACEUTICALS, INC. (US) | 2017-02-07 | — | — | US | disclosed |
| EP-3100723-A1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | Bikam Pharmaceuticals, Inc. (US) | 2016-12-07 | — | — | EP | disclosed |
| EP-2442644-B1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | BIKAM PHARMACEUTICALS INC (US) | 2016-08-10 | — | — | EP | disclosed |
| EP-2442644-A1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | Bikam Pharmaceuticals, Inc. (US) | 2012-04-25 | — | — | EP | disclosed |
| US-20110003784-A1 | Opsin-binding ligands, compositions and methods of use | BIKAM PHARMACEUTICALS INC. | 2011-01-06 | — | — | US | disclosed |
| WO-2010147653-A1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | BIKAM PHARMACEUTICALS, INC. (US) | 2010-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170037018-A1 | Opsin-Binding Ligands, Compositions and Methods of Use | CRYAB, CRYAA, UACA | UGT2B7 3213/4885CYP1A2 4582/4885PTPN2 1993/4885 |
| US-20110003784-A1 | Opsin-binding ligands, compositions and methods of use | CRYAB, CRYAA, UACA | UGT2B7 3213/4885CYP1A2 4582/4885PTPN2 1993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.